JP2013091656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013091656A5 JP2013091656A5 JP2012286473A JP2012286473A JP2013091656A5 JP 2013091656 A5 JP2013091656 A5 JP 2013091656A5 JP 2012286473 A JP2012286473 A JP 2012286473A JP 2012286473 A JP2012286473 A JP 2012286473A JP 2013091656 A5 JP2013091656 A5 JP 2013091656A5
- Authority
- JP
- Japan
- Prior art keywords
- testosterone
- use according
- nandrolone
- pain
- aromatase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 14
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 13
- 239000003098 androgen Substances 0.000 claims 13
- 239000003886 aromatase inhibitor Substances 0.000 claims 13
- 229960000746 testosterone undecanoate Drugs 0.000 claims 8
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims 8
- 229960003604 testosterone Drugs 0.000 claims 7
- 229960002932 anastrozole Drugs 0.000 claims 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 5
- 230000003637 steroidlike Effects 0.000 claims 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 4
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims 4
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- -1 ethylestrelol Nord Chemical compound 0.000 claims 4
- 229960001566 methyltestosterone Drugs 0.000 claims 4
- 229960004719 nandrolone Drugs 0.000 claims 4
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 4
- 229960005244 oxymetholone Drugs 0.000 claims 4
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 claims 4
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 claims 4
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 claims 4
- RZRPTBIGEANTGU-UHFFFAOYSA-N -Androst-4-ene-3,11,17-trione Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)=O)C4C3CCC2=C1 RZRPTBIGEANTGU-UHFFFAOYSA-N 0.000 claims 2
- NZGKYNGOBSDZNY-YNFNDHOQSA-N 17beta-Hydroxyestr-4-en-3-one benzoate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)C1=CC=CC=C1 NZGKYNGOBSDZNY-YNFNDHOQSA-N 0.000 claims 2
- ORGPUALGNXTPAW-UHFFFAOYSA-N 2,6-dichloro-n-(1-cyanocycloheptyl)benzamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1(C#N)CCCCCC1 ORGPUALGNXTPAW-UHFFFAOYSA-N 0.000 claims 2
- ZVHNNCSUTNWKFC-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonyl)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperazine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZVHNNCSUTNWKFC-UHFFFAOYSA-N 0.000 claims 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010000060 Abdominal distension Diseases 0.000 claims 2
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims 2
- QADHLRWLCPCEKT-UHFFFAOYSA-N Androstenediol Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006820 Arthralgia Diseases 0.000 claims 2
- 208000036487 Arthropathies Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006298 Breast pain Diseases 0.000 claims 2
- 206010008479 Chest Pain Diseases 0.000 claims 2
- 206010009866 Cold sweat Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000004483 Dyspareunia Diseases 0.000 claims 2
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000008454 Hyperhidrosis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 206010024264 Lethargy Diseases 0.000 claims 2
- 206010025282 Lymphoedema Diseases 0.000 claims 2
- 208000006662 Mastodynia Diseases 0.000 claims 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims 2
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 claims 2
- 206010027951 Mood swings Diseases 0.000 claims 2
- JKWKMORAXJQQSR-MOPIKTETSA-N Nandrolone Decanoate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 JKWKMORAXJQQSR-MOPIKTETSA-N 0.000 claims 2
- TXLCJMHILCSZJG-QNTYDACNSA-N Nandrolone cyclohexanepropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCCC1 TXLCJMHILCSZJG-QNTYDACNSA-N 0.000 claims 2
- ICNIVTHKZKRHPD-YNFNDHOQSA-N Nandrolone furylpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CO1 ICNIVTHKZKRHPD-YNFNDHOQSA-N 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010030124 Oedema peripheral Diseases 0.000 claims 2
- 206010049088 Osteopenia Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims 2
- 206010040021 Sensory abnormalities Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 claims 2
- DJPZSBANTAQNFN-UHFFFAOYSA-N Testosterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(OC(=O)C)C1(C)CC2 DJPZSBANTAQNFN-UHFFFAOYSA-N 0.000 claims 2
- LBERVHLCXUMDOT-MPZZESAYSA-N Testosterone decanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 LBERVHLCXUMDOT-MPZZESAYSA-N 0.000 claims 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 claims 2
- FDCINQSOYQUNKB-UHFFFAOYSA-N UNPD98205 Natural products C1CC2C3(C)CCC(OC(=O)C)CC3CCC2C2CCC(=O)C21C FDCINQSOYQUNKB-UHFFFAOYSA-N 0.000 claims 2
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 2
- 208000021017 Weight Gain Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- KNDUBESZKGHTSA-CJVRWNGOSA-N [(3r,5s,8r,9s,10s,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound O([C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@H]3CCC1=O)C)C(=O)C1=CC=CC=C1 KNDUBESZKGHTSA-CJVRWNGOSA-N 0.000 claims 2
- SAOVUTZAPBDLOX-WSKGSGNSSA-N [(3r,5s,8r,9s,10s,13s,14s)-10,13-dimethyl-17-oxo-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-yl] propanoate Chemical compound C1C[C@@H]2[C@@]3(C)CC[C@@H](OC(=O)CC)C[C@@H]3CC[C@H]2[C@@H]2CCC(=O)[C@]21C SAOVUTZAPBDLOX-WSKGSGNSSA-N 0.000 claims 2
- QXKRUGDXPWHXHL-FQJIPJFPSA-N [(3s,8r,9s,10r,13s,14s,17s)-17-acetyloxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C1C=C2C[C@@H](OC(C)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 QXKRUGDXPWHXHL-FQJIPJFPSA-N 0.000 claims 2
- OQHMNEGOKQMOFM-BPSSIEEOSA-N [(3s,8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 OQHMNEGOKQMOFM-BPSSIEEOSA-N 0.000 claims 2
- BMDNPBLUVJZAEA-BPSSIEEOSA-N [(3s,8r,9s,10r,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 BMDNPBLUVJZAEA-BPSSIEEOSA-N 0.000 claims 2
- BGSWILYBWIQYKQ-DRKCKIEBSA-N [(3s,8r,9s,10r,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] benzoate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CC[C@H](O)CC4=CC3)C)CC[C@@]21C)C(=O)C1=CC=CC=C1 BGSWILYBWIQYKQ-DRKCKIEBSA-N 0.000 claims 2
- ODZDZTOROXGJAV-IRWJKHRASA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate Chemical compound C1CC(CCCC)CCC1C(=O)O[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 ODZDZTOROXGJAV-IRWJKHRASA-N 0.000 claims 2
- AQMOXBCKEKPDRF-YNFNDHOQSA-N [(8r,9s,10r,13s,14s,17s)-13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl] cyclohexanecarboxylate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)C1CCCCC1 AQMOXBCKEKPDRF-YNFNDHOQSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- RZRPTBIGEANTGU-IRIMSJTPSA-N adrenosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RZRPTBIGEANTGU-IRIMSJTPSA-N 0.000 claims 2
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims 2
- QADHLRWLCPCEKT-LOVVWNRFSA-N androst-5-ene-3beta,17beta-diol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 QADHLRWLCPCEKT-LOVVWNRFSA-N 0.000 claims 2
- 229960003473 androstanolone Drugs 0.000 claims 2
- 229950009148 androstenediol Drugs 0.000 claims 2
- 229960005471 androstenedione Drugs 0.000 claims 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims 2
- 229940061641 androsterone Drugs 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- FFIAPLNALYDYQK-UHFFFAOYSA-L barium(2+);[2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl phosphate Chemical compound [Ba+2].OCC1OC(O)(COP([O-])([O-])=O)C(O)C1O FFIAPLNALYDYQK-UHFFFAOYSA-L 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims 2
- 229960000766 danazol Drugs 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 claims 2
- 229950005101 drostanolone Drugs 0.000 claims 2
- 229950004683 drostanolone propionate Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 150000002596 lactones Chemical class 0.000 claims 2
- 208000002502 lymphedema Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960005272 mesterolone Drugs 0.000 claims 2
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 229960003377 metandienone Drugs 0.000 claims 2
- IKXILDNPCZPPRV-RFMGOVQKSA-N metholone Chemical compound C1C[C@@H]2[C@@]3(C)C[C@@H](C)C(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C IKXILDNPCZPPRV-RFMGOVQKSA-N 0.000 claims 2
- 229960000270 methylestrenolone Drugs 0.000 claims 2
- ZQKOGDIJTMNWCT-UFQCMFJCSA-N methyltestosterone group Chemical group CC1[C@@H]2[C@]([C@H](C1)O)(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C ZQKOGDIJTMNWCT-UFQCMFJCSA-N 0.000 claims 2
- 229960001935 nandrolone decanoate Drugs 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 206010029410 night sweats Diseases 0.000 claims 2
- 230000036565 night sweats Effects 0.000 claims 2
- 229960000492 norethandrolone Drugs 0.000 claims 2
- ZDHCJEIGTNNEMY-XGXHKTLJSA-N norethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 ZDHCJEIGTNNEMY-XGXHKTLJSA-N 0.000 claims 2
- 229960000464 oxandrolone Drugs 0.000 claims 2
- 229960002847 prasterone Drugs 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 229960000249 pregnenolone Drugs 0.000 claims 2
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- GFJWACFSUSFUOG-ZJTJBYBXSA-M sodium dehydroepiandrosterone sulfate Chemical compound [Na+].C1[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 GFJWACFSUSFUOG-ZJTJBYBXSA-M 0.000 claims 2
- 229960000912 stanozolol Drugs 0.000 claims 2
- 230000035900 sweating Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- DJPZSBANTAQNFN-PXQJOHHUSA-N testosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 DJPZSBANTAQNFN-PXQJOHHUSA-N 0.000 claims 2
- 229960003410 testosterone decanoate Drugs 0.000 claims 2
- 229960003484 testosterone enanthate Drugs 0.000 claims 2
- 229960001712 testosterone propionate Drugs 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- 208000010484 vulvovaginitis Diseases 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 229960004421 formestane Drugs 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2005905768 | 2005-10-19 | ||
| AU2005905768A AU2005905768A0 (en) | 2005-10-19 | Therapeutic methods, compositions and kits | |
| US73266205P | 2005-11-03 | 2005-11-03 | |
| US60/732,662 | 2005-11-03 | ||
| US79830806P | 2006-05-08 | 2006-05-08 | |
| US60/798,308 | 2006-05-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535845A Division JP5449775B2 (ja) | 2005-10-19 | 2006-10-18 | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013091656A JP2013091656A (ja) | 2013-05-16 |
| JP2013091656A5 true JP2013091656A5 (https=) | 2013-08-15 |
| JP5762390B2 JP5762390B2 (ja) | 2015-08-12 |
Family
ID=37962114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535845A Expired - Fee Related JP5449775B2 (ja) | 2005-10-19 | 2006-10-18 | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| JP2012286473A Expired - Fee Related JP5762390B2 (ja) | 2005-10-19 | 2012-12-28 | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535845A Expired - Fee Related JP5449775B2 (ja) | 2005-10-19 | 2006-10-18 | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20090215731A1 (https=) |
| EP (1) | EP1945224B1 (https=) |
| JP (2) | JP5449775B2 (https=) |
| CA (1) | CA2626337C (https=) |
| WO (1) | WO2007045027A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5449775B2 (ja) | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| GB0523550D0 (en) * | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| DE102007032468A1 (de) * | 2007-07-10 | 2009-01-15 | Brätter, Christian, Dr. | Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten |
| US20100144687A1 (en) * | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| TR201816243T4 (tr) | 2011-01-31 | 2018-11-21 | Lucolas M D Ltd | Aromataz inhibitörlerinin ve antioksidanların kombinasyonları. |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| GB201222455D0 (en) * | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10201549B2 (en) * | 2013-06-14 | 2019-02-12 | Professional Compounding Centers Of America (Pcca) | Testosterone combined with anastrozole injection solutions |
| CN113101292B (zh) * | 2014-05-08 | 2023-07-11 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US20160022643A1 (en) * | 2014-07-22 | 2016-01-28 | Professional Compounding Centers Of America | Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men |
| US10213440B2 (en) * | 2014-08-20 | 2019-02-26 | Professional Compounding Centers Of America (Pcca) | Oral transmucosal pharmaceutical compositions including testosterone and an aromatase inhibitor |
| CN113633644A (zh) | 2014-10-22 | 2021-11-12 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
| DE102014226903A1 (de) * | 2014-12-23 | 2016-06-23 | Olympus Winter & Ibe Gmbh | HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| JP2018534291A (ja) | 2015-10-22 | 2018-11-22 | ハバフ セラピューティクス ピーティーワイ エルティーディー | マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法 |
| CN105456276A (zh) * | 2015-12-18 | 2016-04-06 | 中国农业大学 | 一种减轻流感病毒感染引起机体损伤的药物 |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| DK3449017T3 (da) | 2016-04-29 | 2022-03-14 | Univ Texas | Målrettet måling af transkriptionel aktivitet vedrørende hormonreceptorer |
| MX394541B (es) * | 2016-05-18 | 2025-03-24 | Tyme Inc | Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancer |
| LT3474841T (lt) * | 2016-06-22 | 2022-06-10 | Ellipses Pharma Ltd | Ar+ krūties vėžio gydymo būdai |
| CA3142193A1 (en) | 2019-06-03 | 2020-12-10 | Havah Therapeutics Pty Ltd | Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use |
| CN115485565A (zh) * | 2020-04-30 | 2022-12-16 | 莱布尼茨实验病毒学研究所 | 用于预测病毒疾病的过程的方法 |
| WO2024234056A1 (en) * | 2023-05-17 | 2024-11-21 | Havah Therapeutics Pty Ltd | Treatment of breast tissue |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4147783A (en) * | 1974-02-28 | 1979-04-03 | Akzona Incorporated | Oral pharmaceutical preparation |
| ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| AU5855794A (en) | 1993-01-19 | 1994-08-15 | Endorecherche Inc. | Therapeutic uses and delivery systems of dehydroepiandrosterone |
| US5824286A (en) | 1994-04-26 | 1998-10-20 | The Medical College Of Hampton Roads | Mammography method |
| DE19610645A1 (de) * | 1996-03-06 | 1997-09-11 | Schering Ag | Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann |
| US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
| US20090264534A1 (en) | 1996-11-27 | 2009-10-22 | Dalton James T | Selective androgen receptor modulators |
| EP1027057A4 (en) | 1997-10-28 | 2003-01-02 | Vivus Inc | TREATMENT OF FEMALE SEXUAL DISORDERS |
| US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| KR20030014223A (ko) * | 2000-05-15 | 2003-02-15 | 파마시아 이탈리아 에스.피.에이. | 항종양제로서의 아로마타제 억제제 및 모노클로날항-ｈｅｒ2 항체 |
| WO2002009721A1 (en) | 2000-07-31 | 2002-02-07 | The Cleveland Clinic Foundation | Method of increasing sensitivity of mammography |
| US8008348B2 (en) | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| EP1401801B1 (en) | 2000-08-24 | 2006-11-02 | The University Of Tennessee Research Corporation | Selective androgen receptor modulators and methods of use thereof |
| WO2002030355A2 (en) * | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| DK1317921T3 (da) * | 2001-12-07 | 2009-12-21 | Besins Mfg Belgium | Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf |
| US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
| AU2003250190A1 (en) * | 2002-07-30 | 2004-02-23 | Novartis Ag | Combination of an aromatase inhibitor with a bisphosphonate |
| AU2003287075A1 (en) | 2002-10-15 | 2004-05-04 | Gtx, Inc. | Treating obesity with selective androgen receptor modulators |
| WO2004035739A2 (en) | 2002-10-16 | 2004-04-29 | Gtx, Inc. | Treating androgen decline in aging male (adam)-associated conditions with sarms |
| CN1168449C (zh) * | 2002-12-23 | 2004-09-29 | 梁有国 | 抗人乳头瘤病毒感染的药物 |
| JP2006516286A (ja) | 2003-01-22 | 2006-06-29 | ジーティーエックス・インコーポレイテッド | Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療 |
| WO2005011705A1 (en) * | 2003-07-25 | 2005-02-10 | Adams Kenneth W | Enhancement of erectile function |
| US20050080062A1 (en) * | 2003-10-09 | 2005-04-14 | Goss Paul E. | Breast cancer treatment regimen |
| KR20060127875A (ko) * | 2004-01-13 | 2006-12-13 | 와이어쓰 | 아로마타제 억제제 요법-관련된 골다공증의 치료 |
| US7138389B2 (en) * | 2004-02-09 | 2006-11-21 | University Of Washington | Oral androgen therapy using modulators of testosterone bioavailability |
| US20050233970A1 (en) * | 2004-03-23 | 2005-10-20 | Praecis Pharmaceuticals, Inc. | Methods for treating long QT syndrome |
| JP2009506119A (ja) | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
| JP5449775B2 (ja) * | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減 |
| US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
| WO2009036566A1 (en) | 2007-09-21 | 2009-03-26 | Mount Sinai Hospital | Methods for detecting abnormalities in breast tissue using aromatase inhibitors |
| US7902147B2 (en) | 2007-11-05 | 2011-03-08 | Duke University | Chronic lymphocytic leukemia prognosis and treatment |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| US8980840B2 (en) | 2009-01-13 | 2015-03-17 | Schepens Eye Research Institute | Therapeutic modulation of vaginal epithelium boundary lubrication |
| WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| CA2853965A1 (en) | 2011-11-03 | 2013-05-10 | Gtx, Inc. | Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof |
| PT2872482T (pt) | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US20140162991A1 (en) | 2012-11-29 | 2014-06-12 | Rebecca L. Glaser | Testosterone-anastrozole (t + a) combination implants in the neo-adjuvant, local and systemic therapy of newly diagnosed, previously untreated breast cancer |
-
2006
- 2006-10-18 JP JP2008535845A patent/JP5449775B2/ja not_active Expired - Fee Related
- 2006-10-18 WO PCT/AU2006/001539 patent/WO2007045027A1/en not_active Ceased
- 2006-10-18 CA CA2626337A patent/CA2626337C/en not_active Expired - Fee Related
- 2006-10-18 US US12/083,771 patent/US20090215731A1/en not_active Abandoned
- 2006-10-18 EP EP06804410A patent/EP1945224B1/en active Active
-
2012
- 2012-01-19 US US13/354,103 patent/US9168302B2/en active Active
- 2012-12-28 JP JP2012286473A patent/JP5762390B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-14 US US14/853,130 patent/US9616072B2/en active Active
-
2018
- 2018-05-25 US US15/990,316 patent/US10765684B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013091656A5 (https=) | ||
| JP2009511609A5 (https=) | ||
| JP2004520320A5 (https=) | ||
| CN1439375B (zh) | 脱氢表雄酮的制药用途 | |
| CA2666829C (en) | Use of estradiol valerate or 17.beta.-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido | |
| AR068702A1 (es) | Composiciones farmaceuticas | |
| CA2431834A1 (en) | Methods and formulations for the treatment of female sexual dysfunction | |
| Surampudi et al. | Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive | |
| CN102357247A (zh) | 脱氢表雄酮的治疗用途和传送系统 | |
| Maruo et al. | Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas | |
| EA201300019A1 (ru) | Способы лечения или предотвращения эстрогензависимых заболеваний | |
| AR099713A1 (es) | Tratamiento de los síntomas o enfermedades por deficiencia masculina de andrógenos con precursores de esteroides sexuales combinados con serm | |
| JP2005532350A (ja) | 新しいエトノゲストレルエステル | |
| Gupta et al. | A comparative study of CEE, tibolone, and DHEA as hormone replacement therapy for surgical menopause | |
| JP2013500324A5 (https=) | ||
| Sánchez-Borrego et al. | Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients | |
| US10300077B2 (en) | Compositions and methods for treating dementia | |
| CA3121359A1 (en) | Medication against estrogen-receptor .beta. (er.beta.) positive breast tumor | |
| Roeca et al. | Menopause as a Manifestation of Aging | |
| Jarząbek-Bielecka et al. | The impact of oral contraception with ethinyl estradiol and chlormadinone acetate on sexual function of women | |
| Rogosnitzky et al. | Testosterone for the Treatment of Mammary and Prostate Cancers: Historical Perspectives and New Directions | |
| Bouchard et al. | Effect of intravaginal Prasterone (DHEA) on libido and sexual dysfunction in postmenopausal women | |
| Rigby | Chronic disease management: Menopause | |
| Nappi et al. | EFFECTS OF SURGICAL AND ADJUVANT THERAPIES FOR BREAST CANCER ON SEXUALITY, COGNITIVE FUNCTIONS AND WEIGHT | |
| Panay et al. | TESTOSTERONE FOR TREATMENT OF HSDD IN NATURALLY MENOPAUSAL WOMEN: THE ADORE STUDY |